Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Celebrating 90 years of innovation #UCB90
Twitter Feed
-
This week our #WorldOsteoporosisDay patient survey was launched. Of those diagnosed with #osteoporosis or #fragilityfractures, how many do you think discussed their future #fragilityfracture risk with their healthcare professional? Find out more: https:/
— UCB News (@ucb_news) 20.10.2018 -
In our #WorldOsteoporosisDay patient survey over half of respondents believed that #fragilityfractures in older age are a result of an unlucky fall or accident. However, they can be the result of #osteoporosis. Find out more: https://t.co/jwiw2fDtSJ https
— UCB News (@ucb_news) 20.10.2018 -
Our new survey, launched today to mark #WorldOsteoporosisDay, has revealed that nearly two thirds of respondents had little or no knowledge of the condition. Discover more about #fragilityfractures and #osteoporosis at: https://t.co/mCp191WkP9 https://t.c
— UCB News (@ucb_news) 20.10.2018
Highlights
UCB Ventures, a strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases, has announced its first direct investment.
